Evoke Pharma Inc reports results for the quarter ended December 31 - Earnings Summary

Evoke Pharma

14/03/2025 19:04

Evoke Pharma Inc EVOK.OQ reported a quarterly adjusted loss of 63 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-7.08.  The lone analyst forecast for the quarter was for a loss of 63 cents per share.

Revenue rose 97.4% to $3.31 million from a year ago; analysts expected $3.08 million.

Evoke Pharma Inc's reported EPS for the quarter was a loss of 63 cents​.

The company reported a quarterly loss of $1.19 million.

Evoke Pharma Inc shares had fallen by 13.0% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Evoke Pharma Inc is $18.00

This summary was machine generated from LSEG data March 14 at 07:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.63
-0.63
Met
Sep. 30 2024
-0.38
-0.94
Missed
Jun. 30 2024
-0.72
-0.93
Missed
Mar. 31 2024
-2.52
-2.04
Beat